283 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
POSTER SESSIONS
275
German language Session
002
Development of a selective fluorescence-labeled
ligand for binding studies and characterization of
lateral mobility of 5-HT2A-receptors on living cells
Stefan Aatz, Germany
Thomas Sorkalla, Sebastian Franken, Christiane Kolb,
Heba Abdel-Aziz, Hanns Haeberlein
003
Patients with high levels of brain-derived
neurotrophic factor (BDNF) show a normalization
of memory impairment during antidepressant
treatment
Jan Engelmann, Germany
Stefanie Wagner, Konrad Schlicht, Nadine Dreimüller,
Marianne B. Müller, André Tadic, Klaus Lieb
004
Deleterious effects of antidepressants on
semen parameters: a case report
Khalid Shehatto, Egypt
Manal Abed, Ahmed El-Aghoury
005
Usefulness of intravenous clomipramine on in-
patients with refractory major depressive disorder
Kazuaki Sugawara, Japan
Toshiyuki Kobayashi
006
Can mirtazapine and bupropion be alternative
medicines for depressed patients at risk for bleeding?
Han-Yong Jung, Republic of Korea
Se-Hoon Shim, Kyoung-Sae Na
007
ECT has greater efficacy than fluoxetine in alle-
viating the burden of illness for patients with major
depressive disorder – a Taiwanese pooled analysis
Ching-Hua Lin, Taiwan
Ming-Chao Chen, Fu-Chiang Wang
008
Effect of vortioxetine versus paroxetina on
sexual functioning
Esther Mancha Heredero, Spain
María Jesús Leñero Navarrete, Yanira D'Hiver Cantalejo,
Héctor Saiz García, Cristina Blanco Dorado, Angela Sofía
Rosero Enríquez, Alejandro Ballesteros Prados
009
Drug interactions in chronic pain disorder,
addiction and affective disorder – clinic, treatment
and TDM
Ivana Adamovic, Germany
010
Readmissions for bipolar affective disorder:
pharmacological approach at discharge in a special-
ized unit in Lisbon
Marco Gonçalves, Portugal
Inês Coelho, Miguel Nascimento, Mariana Silva,
Joana Aguiar
011
Alpha1 and alpha2 adrenoceptors as targets of
antidepressant and antipsychotic drugs: insights
from serum reference levels and in vitro-binding
affinity patterns
Tabea von der Lühe, Germany
Julia Christl, Christian Lange-Asschenfeldt
012
A phase 3, multicenter randomized double
blind placebo controlled study of the opioid receptor
antagonist – odelepran the treatment of alcohol
addiction
Elvira Mukhamettshina, Russia
013
Genotyping and phenotyping of CYP2D6 and
CYP3A isoenzymes in patience with alcohol use
disorder: relationship with haloperidol plasmatic
concentration, efficacy of pharmacotherapy and risk
of adverse drug reactions
Mikhail Zastrozhin, Russia
Dmitry Sychev, Igor Miroshnichenko, Elena Grishina,
Valery Smirnov, Evgeny Bryun
014
New safety signals
Annette Viktoria Hinze, Germany
Walburga Lütkehermölle, Martin Huber, Christine
Greiner
015
Characteristics of severe hyponatremia in pa-
tients with psychiatric illness: a retrospective study
Eriko Makino, Japan
Tetsuro Enomoto, Takahide Hashimoto, Hidetaka
Hamasaki, Akahito Sako, Hidekatsu Yanai, Hideki
Nanasawa, Tatsuro Hayakawa
P-35
Poster Session
13:30– 15:00
|
Hall Budapest
TOPIC 18:
Pharmacotherapy
Pharmacotherapy II
Chair:
Ekkehard Haen, Germany
001
A study to assess the prophylactic and ther-
apeutic effect of enalapril on olanzapine-induced
metabolic syndrome in wistar rats
Veena Nayak, India
Avinash A., Kurady Laxminarayana Bairy, Sushil Kiran
Kunder
002
May quetiapine plus sertraline cause bell's
palsy? Two case reports
Mohammadreza Shalbafan, Iran
Farzaneh Malekpour
003
Predictors of response to celecoxib augmen-
tation of olanzapine therapy in schizophrenia in a
randomized, double blind, controlled study
Kabir Garg, India
Anil Nischal, Anuradha Nischal, Adarsh Tripathi, Manu
Agarwal
004
Relationship between antipsychotic treatment
and metabolic parameters in a group of patients
with severe mental disorder and sedentary lifestyle
Luisa San Emeterio, Spain
M. Teresa Salvador, Silvia Oller, Luis Miguel Martin,
Roser Masa, M. Isabel Fernandez